drugset / Trial / NCT01025648

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

NCT01025648

Phase 1/2 Terminated 9 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to identify the optimum E004 dose strength(s) for the ensuing pivotal clinical trials. The study will be conducted in adult patients who have intermittent, or mild-to-moderate persistent, asthma, but are otherwise healthy. The bronchodilatory efficacy of E004, is evaluated in terms of post-dose area under the curves (AUC) of FEV1 changes (% and volumes), from the pre-dose baseline values, in comparison to the Placebo Control and the Active Control.

Timeline

Start
2009-12
Primary completion
2009-12
Completion
2009-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 90 ug Inhaled
Subject Epinephrine Other / unclassified 125 ug Inhaled
Subject Epinephrine Other / unclassified 160 ug Inhaled
Subject Epinephrine Other / unclassified 220 ug Inhaled

Indications